Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients.

Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet (2005) 1.66

Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol (2009) 1.58

Retracted Effects of a pre-visit educational website on information recall and needs fulfilment in breast cancer genetic counselling, a randomized controlled trial. Breast Cancer Res (2012) 1.54

Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test (2008) 1.46

Guidelines for disclosing genetic information to family members: from development to use. Fam Cancer (2006) 1.23

Sharing genetic risk with next generation: mutation-positive parents' communication with their offspring in Lynch Syndrome. Fam Cancer (2011) 1.23

Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol (2008) 1.20

Informing one's family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer (2005) 1.15

Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients. Fam Cancer (2005) 1.15

Hereditary nonpolyposis colorectal cancer family members' perceptions about the duty to inform and health professionals' role in disseminating genetic information. Genet Test (2005) 1.05

Returning a Research Participant's Genomic Results to Relatives: Analysis and Recommendations. J Law Med Ethics (2015) 1.02

A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer (2011) 1.01

Cancer genetic counseling: communication and counselees' post-visit satisfaction, cognitions, anxiety, and needs fulfillment. J Genet Couns (2007) 0.99

Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information. Eur J Hum Genet (2009) 0.99

Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing. J Med Genet (2007) 0.97

Communication of BRCA results and family testing in 1,103 high-risk women. Cancer Epidemiol Biomarkers Prev (2010) 0.96

Disclosure of genetic information within families. Am J Nurs (2009) 0.95

Colorectal cancer in the family: psychosocial distress and social issues in the years following genetic counselling. Hered Cancer Clin Pract (2007) 0.93

Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer (2011) 0.92

Gynecologic cancer prevention and control in the National Comprehensive Cancer Control Program: progress, current activities, and future directions. J Womens Health (Larchmt) (2013) 0.91

A family genetic risk communication framework: guiding tool development in genetics health services. J Community Genet (2013) 0.90

Ethical issues of predictive genetic testing for diabetes. J Diabetes Sci Technol (2009) 0.89

A clinical perspective on ethical arguments around prenatal diagnosis and preimplantation genetic diagnosis for later onset inherited cancer predispositions. Fam Cancer (2009) 0.89

The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling. J Genet Couns (2008) 0.88

Informing relatives about their hereditary or familial cancer risk: study protocol for a randomized controlled trial. Trials (2014) 0.87

Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun (2009) 0.87

Unpacking the blockers: understanding perceptions and social constraints of health communication in hereditary breast ovarian cancer (HBOC) susceptibility families. J Genet Couns (2011) 0.85

Men in the women's world of hereditary breast and ovarian cancer--a systematic review. Fam Cancer (2009) 0.84

Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic. J Genet Couns (2013) 0.83

A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome. Hered Cancer Clin Pract (2012) 0.83

Psychometric testing of the decisional conflict scale: genetic testing hereditary breast and ovarian cancer. Nurs Res (2011) 0.82

Improving family communication after a new genetic diagnosis: a randomised controlled trial of a genetic counselling intervention. BMC Med Genet (2014) 0.82

An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations. Fam Cancer (2011) 0.82

Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers? J Cancer Epidemiol (2012) 0.81

Breast cancer genetic counselling referrals: how comparable are the findings between the UK and the Netherlands? J Community Genet (2011) 0.80

Disclosing cancer genetic information within families: perspectives of counselees and their at-risk relatives. Fam Cancer (2010) 0.80

A pre-visit tailored website enhances counselees' realistic expectations and knowledge and fulfils information needs for breast cancer genetic counselling. Fam Cancer (2012) 0.80

Intrafamilial disclosure of risk for hereditary breast and ovarian cancer: points to consider. J Community Genet (2012) 0.79

Outcomes of a randomised controlled trial of a complex genetic counselling intervention to improve family communication. Eur J Hum Genet (2015) 0.78

Factors affecting encouragement of relatives among families with Lynch syndrome to seek medical assessment. Fam Cancer (2011) 0.78

Women's satisfaction with genetic counseling for hereditary breast-ovarian cancer: psychological aspects. Am J Med Genet A (2004) 0.78

Breast cancer in the young: role of the geneticist. J Thorac Dis (2013) 0.78

Prevalence and correlates of receiving and sharing high-penetrance cancer genetic test results: findings from the Health Information National Trends Survey. Public Health Genomics (2015) 0.78

The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. Fam Cancer (2016) 0.77

Family Ties: The Role of Family Context in Family Health History Communication About Cancer. J Health Commun (2016) 0.76

The impact of participation in genetic research for families with cleft lip with and without cleft palate: a qualitative study. J Community Genet (2014) 0.75

A tale worth telling: the impact of the diagnosis experience on disclosure of genetic disorders. J Intellect Disabil Res (2014) 0.75

Design and Feasibility of an Intervention to Support Cancer Genetic Counselees in Informing their At-Risk Relatives. J Genet Couns (2016) 0.75

Methodology in longitudinal studies on psychological effects of predictive DNA testing: a review. J Med Genet (2004) 0.75

Ethicolegal aspects of genetics in surgical practice. Ann R Coll Surg Engl (2009) 0.75

Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study. Fam Cancer (2016) 0.75

The establishment of an ethical guideline for genetic testing through citizen consensus via the Internet in Taiwan. J Med Internet Res (2010) 0.75

Recontacting participants for expanded uses of existing samples and data: a case study. Genet Med (2017) 0.75

The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49

A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet (2004) 2.97

Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA (2009) 2.72

Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55

CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur J Hum Genet (2005) 2.37

Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol (2009) 2.32

Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion. Nat Genet (2006) 2.11

Ophthalmological assessment of children with neurofibromatosis type 1. Eur J Pediatr (2013) 1.99

Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet (2003) 1.84

Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Lancet Neurol (2013) 1.74

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68

Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study. J Neurol (2004) 1.64

Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations. Eur J Hum Genet (2009) 1.58

Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders. Eur J Hum Genet (2011) 1.57

Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc Natl Acad Sci U S A (2004) 1.56

Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nat Genet (2003) 1.54

Screening for FMR-1 premutations in 122 older Flemish males presenting with ataxia. Eur J Hum Genet (2005) 1.49

Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. Eur J Hum Genet (2003) 1.47

Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study. Hum Mutat (2005) 1.39

Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer (2011) 1.36

Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet (2007) 1.33

Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat (2006) 1.29

Psychological distress in the 5-year period after predictive testing for Huntington's disease. Eur J Hum Genet (2003) 1.23

Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum Mutat (2005) 1.23

Spred1 is required for synaptic plasticity and hippocampus-dependent learning. J Neurosci (2008) 1.22

Predictive testing for hereditary nonpolyposis colorectal cancer: subjective perception regarding colorectal and endometrial cancer, distress, and health-related behavior at one year post-test. Genet Test (2005) 1.19

Predictive testing for hereditary non-polyposis colorectal cancer: motivation, illness representations and short-term psychological impact. Patient Educ Couns (2004) 1.18

Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis (2004) 1.15

Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. Proc Natl Acad Sci U S A (2010) 1.14

Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat (2012) 1.13

Legius syndrome, an Update. Molecular pathology of mutations in SPRED1. Keio J Med (2013) 1.10

The complexity of reproductive decision-making in asymptomatic carriers of the Huntington mutation. Eur J Hum Genet (2007) 1.10

The interface between assisted reproductive technologies and genetics: technical, social, ethical and legal issues. Eur J Hum Genet (2006) 1.07

Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat (2008) 1.07

The impact of a high-grade glioma on everyday life: a systematic review from the patient's and caregiver's perspective. Eur J Oncol Nurs (2012) 1.04

Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology (2006) 1.03

Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association. Cancer Res (2009) 1.01

What's new in the neuro-cardio-facial-cutaneous syndromes? Eur J Pediatr (2007) 0.99

What the neurosurgeon should know about hemangioblastoma, both sporadic and in Von Hippel-Lindau disease: A literature review. Surg Neurol Int (2013) 0.98

Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients. Genes Chromosomes Cancer (2006) 0.97

Has the prevalence of congenital abnormalities after intracytoplasmic sperm injection increased? The Leuven data 1994-2000 and a review of the literature. Gynecol Obstet Invest (2010) 0.96

Legius syndrome in fourteen families. Hum Mutat (2011) 0.95

Autism spectrum disorder profile in neurofibromatosis type I. J Autism Dev Disord (2015) 0.93

Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1. Am J Med Genet B Neuropsychiatr Genet (2014) 0.92

The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A (2012) 0.91

Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1. J Med Genet (2010) 0.91

Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. Genes Chromosomes Cancer (2010) 0.89

Re-evaluation of MRX36 family after discovery of an ARX gene mutation reveals mild neurological features of Partington syndrome. Am J Med Genet (2002) 0.89

Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med (2005) 0.89

Observations on intelligence and behavior in 15 patients with Legius syndrome. Am J Med Genet C Semin Med Genet (2011) 0.89

Methylation defect in imprinted genes detected in patients with an Albright's hereditary osteodystrophy like phenotype and platelet Gs hypofunction. PLoS One (2012) 0.89

Diagnostic genetic testing for hereditary breast and ovarian cancer in cancer patients: women's looking back on the pre-test period and a psychological evaluation. Genet Test (2004) 0.88

Genomic organization and evolution of the NF1 microdeletion region. Genomics (2004) 0.87

Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas. Eur J Hum Genet (2011) 0.86

PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning. Eur J Hum Genet (2003) 0.86

Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation. Pediatr Blood Cancer (2007) 0.86

Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-associated glomus tumors. Genes Chromosomes Cancer (2012) 0.86

Biallelic inactivation of NF1 in a sporadic plexiform neurofibroma. Genes Chromosomes Cancer (2012) 0.85

Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways. Hum Mutat (2009) 0.85

Real-time quantitative allele discrimination assay using 3' locked nucleic acid primers for detection of low-percentage mosaic mutations. Anal Biochem (2006) 0.85

Multiple pilomatricomas with somatic CTNNB1 mutations in children with constitutive mismatch repair deficiency. Genes Chromosomes Cancer (2013) 0.84

Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery. PLoS Genet (2013) 0.84

Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us? Breast Cancer Res Treat (2007) 0.84

Cardiac involvement and CTG expansion in myotonic dystrophy. J Neurol (2002) 0.83

Prenatal testing for Huntington's disease: a European collaborative study. Eur J Hum Genet (2002) 0.83

SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints. Genome Biol (2014) 0.82

The development of a clinical screening instrument for tumour predisposition syndromes in childhood cancer patients. Eur J Cancer (2013) 0.82

CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A (2014) 0.81

Partners of mutation-carriers for Huntington's disease: forgotten persons? Eur J Hum Genet (2005) 0.81

Investigation of gene dosage imbalances in patients with Noonan syndrome using multiplex ligation-dependent probe amplification analysis. Eur J Med Genet (2010) 0.81

Copy number variations in the NF1 gene region are infrequent and do not predispose to recurrent type-1 deletions. Eur J Hum Genet (2008) 0.80

Clinical and hematologic findings in Noonan syndrome patients with PTPN11 gene mutations. Am J Med Genet A (2010) 0.80

Pathogenesis of vestibular schwannoma in ring chromosome 22. BMC Med Genet (2009) 0.79

Multiple orbital neurofibromas, painful peripheral nerve tumors, distinctive face and marfanoid habitus: a new syndrome. Eur J Hum Genet (2012) 0.79

Detection of delirium in palliative care unit patients: a prospective descriptive study of the Delirium Observation Screening Scale administered by bedside nurses. Palliat Med (2013) 0.79

Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD). Eur J Hum Genet (2002) 0.78

Gustatory flushing (auriculotemporal nerve syndrome) in children with neurofibromatosis type 1 and facial plexiform neurofibromas. J Pediatr (2011) 0.78

A distinct neurocognitive phenotype in female fragile-X premutation carriers assessed with visual attention tasks. Am J Med Genet A (2003) 0.77

An 8.9 year old girl with autism and Gorlin syndrome. Eur J Paediatr Neurol (2010) 0.77

Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3 NF1 deletions. Hum Mutat (2011) 0.77

Juvenile xanthogranuloma of the corneoscleral limbus: report of two cases. Ophthalmic Genet (2010) 0.77

Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? Int J Gynecol Cancer (2009) 0.76